Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1;

          -  Subjects who are chemotherapy naive and have Stage IIIB-IV non-squamous NSCLC;

          -  Gene diagnostic tests must show that subjects are with wild type of EGFR, ALK and
             ROS1;

          -  Known PD-L1 status as determined by immunohistochemistry assay performed on previously
             obtained archival tumor tissue or tissue obtained from a biopsy at screening;

          -  No prior systemic treatment;

          -  Adequate hematologic and end organ function;

          -  Female participants of childbearing potential must have a negative serum pregnancy
             test within -7 days of randomization and must be willing to use very efficient barrier
             methods of contraception or a barrier method plus a hormonal method starting with the
             screening visit through 6 months after the last dose Male participants with a female
             partner(s) of child-bearing potential must be willing to use very efficient barrier
             methods of contraception from screening through 6 months after the last dose.

        Exclusion Criteria:

          -  Significant cardiovascular disease;

          -  Prior treatment with immune checkpoint blockade therapies, anti-programmed death-1,
             and anti-PD-L1 therapeutic antibodies;

          -  History of autoimmune disease;

          -  Malignancies other than NSCLC within 5 years prior to randomization, with the
             exception of those with a negligible risk of metastasis or death treated with expected
             curative outcome;

          -  Severe infection within 4 weeks prior to randomization;

          -  Administration of a live, attenuated vaccine within 4 weeks before randomization or
             anticipation that such a live attenuated vaccine will be required during the study;

          -  Major surgical procedure within 4 weeks prior to randomization;

          -  History of hemoptysis within 12 weeks prior to randomization;

          -  Inadequately controlled hypertension;

          -  Evidence of bleeding diathesis or coagulopathy;

          -  Prior allogeneic bone marrow transplantation or solid organ transplant;

          -  Positive test for HIV, and patients with active hepatitis B or hepatitis C.